New Strategies for Dealing with Staphylococcus aureus Colonization and the Emerging Methicillin-Resistant Staphylococcus aureu s Epidemic in Atopic Dermatitis

Division of Pediatric Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, CO 80206, USA.
Progress in allergy 03/2012; 96:113-9. DOI: 10.1159/000331910
Source: PubMed


Atopic dermatitis is a common inflammatory skin disease and a global health problem. Patients are often colonized or infected by Staphylococcus aureus, usually by toxin-producing strains. Methicillin-resistant S. aureus (MRSA) has emerged as an important pathogen. Community-acquired MRSA, a frequent cause of skin and soft tissue infections has become epidemic. Basic skin care measures emphasizing repair and protection of the skin barrier reduce microbial colonization and decrease the need for specific antimicrobial therapy even in patients colonized by MRSA. Novel approaches directed at S. aureus colonization and prevention of infection include compounds mimicking antimicrobial peptides, vaccines targeting unique antigens and toxin-neutralizing agents.

1 Follower
3 Reads
  • The Journal of allergy and clinical immunology 08/2013; 132(2):511-512.e5. DOI:10.1016/j.jaci.2013.06.030 · 11.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of recurrent skin and soft tissue infections. For patients with atopic dermatitis, recurrent skin infections with MRSA often lead to eczema exacerbation. There currently is no standard practice in the prevention of recurrent MRSA soft tissue infections in the general and the atopic dermatitis populations. The current article reviews recent data on S aureus decolonization treatments for the prevention of recurrent MRSA soft tissue infections in the community setting.
    07/2014; 2(4). DOI:10.1016/j.jaip.2014.04.007
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atopic dermatitis is the most common chronic inflammatory skin disease. Its pathogenesis combines barrier defects, immune dysregulation, and increased skin infections; however, the relative contribution of each of these components is yet to be determined. Uninvolved atopic dermatitis skin also displays broad immune and barrier abnormalities, which highlights a role for proactive treatment strategy. The residual disease genomic profile that accompanies clinical resolution provides further support for proactive treatment approaches. Although intrinsic and extrinsic atopic dermatitis subtypes share a common clinical phenotype, they show some important differences in their Th22/Th17 cytokine profile, which opens the door for personalized specific therapeutics for each disease category.
    07/2014; 2(4). DOI:10.1016/j.jaip.2014.03.006